Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.84)
# 1,633
Out of 5,118 analysts
46
Total ratings
37.14%
Success rate
53.78%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Upgrades: Buy | $18 | $13.19 | +36.47% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $8.26 | +81.60% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.95 | +544.07% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.27 | +126.07% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.09 | +1,918.35% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $7.93 | +202.65% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $26.62 | +369.57% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.35 | +437.31% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.27 | +481.04% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.30 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $186.85 | -57.63% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $101.93 | +52.07% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.99 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.43 | +928.81% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.91 | +36,559.88% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $37.59 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.65 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.48 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.56 | +58,493.75% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.49 | +60,302.68% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.82 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.08 | +1,265.89% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $220.41 | +2.08% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $6.30 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.64 | - | 2 | Jan 4, 2017 |
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $13.19
Upside: +36.47%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $8.26
Upside: +81.60%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.95
Upside: +544.07%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.27
Upside: +126.07%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.09
Upside: +1,918.35%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $7.93
Upside: +202.65%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $26.62
Upside: +369.57%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.35
Upside: +437.31%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.27
Upside: +481.04%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.30
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $186.85
Upside: -57.63%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $101.93
Upside: +52.07%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.99
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $2.43
Upside: +928.81%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.91
Upside: +36,559.88%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $37.59
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.65
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.48
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.56
Upside: +58,493.75%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.49
Upside: +60,302.68%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.82
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.08
Upside: +1,265.89%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $220.41
Upside: +2.08%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $6.30
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.64
Upside: -